In another study, among the 36 parameters analyzed across 21 cancer types, the estimated CD8+ T-cell abundance in TME was the most predictive of the response to anti-PD-1/PD-L1 therapy, followed by the TMB and by the fraction of samples with high PD-1 gene expression. The gene discussed is CD274; the disease is cancer.